The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA

作者：Hojjat Ahmadzadehfar, Kamran Aryana, Elahe Pirayesh, Saeed Farzanehfar, Majid Assadi, Babak Fallahi, Babak Shafiei, Narjess Ayati, Mahasti Amoui · 发表于：Iranian Journal of Nuclear Medicine · 年份：2018 · 被引用次数：19 · 研究领域：Prostate Cancer Treatment and Research、Radiopharmaceutical Chemistry and Applications、Lung Cancer Treatments and Mutations

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with continuously increasing interest and use worldwide. This guideline is intended to assist nuclear medicine physicians in evaluating and managing patients with mRCPC for whom radioligand therapy (RLT) using 177Lu-PSMA is a promising treatment option. In addition, more information could be provided by subsequent investigative studies in the field of RLT.